IGF2-AS

Across TCGA pan-cancer cohorts, IGF2-AS mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated IGF2-AS data layer compared with 24 for mass-spec protein.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher IGF2-AS mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated IGF2-AS expression acts as an unfavorable survival marker, although some lineages such as LUAD and GBM show a favorable association.

LUAD, GBM, and LSCC are the cancer types where IGF2-AS mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Quartile	II,III,IV	1.000	0.261	.024	6	view →
GBM	OS	Median	All	0.436	0.300	.029	4	view →
LSCC	OS	Quartile	III,IV	0.943	0.662	.045	2	view →
HNSC	DFS	Median	III,IV	0.612	0.934	.030	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

IGF2-AS–LUAD (OS)

Open the LUAD breakdown →